CD19 and acute lymphoblastic leukemia: Lastly, in an acute lymphoblastic leukemia model, administration of human PBMCs transduced with TetCAR into NSG mice bearing CD19-expressing NALM6 tumors was able to significantly reduce, but not clear tumor burden.